Once there was…
For more than a century, organic chemistry lived by a simple, stabilizing assumption: double bonds behave best when they’re flat and planar. And one rule in particular—Bredt’s rule—served as a firm boundary line, warning chemists away from placing double bonds at bridgehead positions in rigid, bridged bicyclic molecules. That “impossible” territory stayed mostly untouched, not because curiosity was lacking, but because the rules said the molecules wouldn’t survive.
Every day,
Drug discovery pushed forward anyway—often with molecular parts that are comparatively flat. But biology isn’t flat. Proteins, binding pockets, and active sites are three-dimensional, irregular landscapes. As modern pharmaceuticals increasingly require precise shapes to target biological sites effectively, medicinal chemists have faced a growing demand for rigid, complex 3D molecular scaffolds—novel building blocks that can “fit” biology more naturally than planar structures.
Yet the toolbox kept returning the same comfortable parts. The need for new 3D structures became louder, while foundational chemistry assumptions seemed to keep the door closed.
Until one day,
UCLA chemists opened that door.
In 2024, Neil Garg’s UCLA team broke through a long-standing barrier by violating Bredt’s rule—showing that double bonds at bridgehead positions could, under the right conditions, be made real. That single result didn’t just add a new molecule to the catalog; it challenged a 100-year-old rule that had shaped what chemists believed was even worth attempting.
Because of that,
They went further—into even more strained, three-dimensional territory that textbooks effectively told chemists to avoid.
Now, UCLA chemists have overturned a 100-year-old rule in organic chemistry again by synthesizing cage-shaped molecules like cubene and quadricyclene with distorted, non-flat double bonds, potentially revolutionizing drug design. These are not slight deviations from the norm: the work creates even more strained 3D structures previously deemed impossible. The double bonds in these molecules are twisted into three-dimensional shapes, directly challenging the standard assumption that such bonds must be planar.
This wasn’t just theoretical provocation. The team backed the claim with experimental synthesis, computational modeling by collaborator Ken Houk, and evidence that these compounds can exist—at least transiently, despite extreme instability. The findings were published in Nature Chemistry, led by Neil Garg’s UCLA team, and funded by the National Institutes of Health—a signal that the implications reach well beyond an elegant chemistry stunt.
Because of that,
Applied science and biomedical fields suddenly have a new direction to explore.
The key implications are immediate and practical:
- Rigid, complex 3D molecular scaffolds become more available—exactly the kind of shapes that can improve pharmaceutical targeting and selectivity.
- The work provides a blueprint for making highly strained, 3D cage-like building blocks, expanding the chemical space available to drug discovery at a time when flat structures are becoming insufficient.
- It underscores a deeper lesson: foundational “rules” can be powerful guides—but they can also limit innovation when treated as immovable laws.
In other words, this breakthrough isn’t only about cubene or quadricyclene. It’s about expanding what chemists can design, what medicinal chemists can build, and what kinds of therapies might become possible when molecular shape stops being constrained by inherited assumptions.
Ever since then,
Chemists are being reminded—by real molecules in real flasks—that the boundaries of organic chemistry are not as fixed as the old rules implied.
As the demand for novel drug-like structures grows, this kind of work may become a turning point: not merely revising a footnote in organic chemistry, but reshaping the scaffold library that future medicines are built from. And perhaps most importantly, it highlights the need to revisit foundational chemistry rules—not to discard them, but to challenge them when innovation depends on it.
Leave a Reply